Loading…
Avlon Industries, Inc. was cited for significant Current Good Manufacturing Practice (CGMP) violations in the manufacturing of over-the-counter (OTC) drug products at its Melrose Park, Illinois facility during a January 2023 inspection. The company failed to conduct identity testing on incoming components (including active ingredients, glycerin, and water) prior to manufacturing and improperly relied on unqualified suppliers' certificates of analysis instead of independently verifying component specifications for purity, strength, and quality. The firm's February 2023 response to the warning was deemed inadequate due to insufficient detail and evidence of corrective actions necessary to achieve CGMP compliance.